Advertisement
Canadian Journal of Cardiology

Positive Recommendation for Angiotensin Receptor–Neprilysin Inhibitor: First Medication Approval for Heart Failure Without Reduced Ejection Fraction

  • Jonathan G. Howlett
    Correspondence
    Corresponding author: Dr Jonathan G. Howlett, Room C-838, 1403 29th Street NW, Calgary, Alberta T2N 2T9, Canada. Phone: +1-403-944-3232; fax: +1-403-944-3262.
    Affiliations
    Division of Cardiology, Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
    Search for articles by this author
Published:January 19, 2021DOI:https://doi.org/10.1016/j.cjca.2021.01.013
      Heart failure (HF) is a problem of epidemic proportions in Western societies; it is a major public health burden and source of morbidity and mortality. Traditionally, HF has been categorised according to left ventricular systolic function. Patients with heart failure and left ventricular ejection fraction (LVEF) < 40% have been referred to as having HF with reduced ejection fraction (HFrEF), and those with higher LVEF as having HF with preserved ejection fraction (HFpEF). Although these two HF types are quite similar in terms of clinical presentation, rate of hospitalisation, quality of life, and symptom and caregiver burdens, fundamental differences remain.
      • Boulet J.
      • Massie E.
      • Rouleau J.L.
      Heart failure with midrange ejection fraction—what is it, if anything?.
      Unlike HFrEF, for which 6 approved medication classes exist for treatment to reduce CV mortality, there are no approved therapies for the nearly 300,000 patients with HFpEF in Canada. In addition, HFpEF is increasingly common and is responsible for approximately 50% of prevalent HF and for 75,000 annual hospitalisations in Canada. This has resulted in a large unmet clinical need for patients affected by HFpEF.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Boulet J.
        • Massie E.
        • Rouleau J.L.
        Heart failure with midrange ejection fraction—what is it, if anything?.
        Can J Cardiol. 2021; 37: 585-594
        • McMurray J.J.
        • Packer M.
        • Desai A.S.
        • et al.
        Angiotensin-neprilysin inhibition versus enalapril in heart failure.
        N Engl J Med. 2014; 371: 993-1004
        • Solomon S.D.
        • Vaduganathan M.
        • B L.C.
        • et al.
        Sacubitril/valsartan across the spectrum of ejection fraction in heart failure.
        Circulation. 2020; 141: 352-361
        • Lund L.H.
        • Claggett B.
        • Liu J.
        • et al.
        Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
        Eur J Heart Fail. 2018; 20: 1230-1239
        • Solomon S.D.
        • Claggett B.
        • Lewis E.F.
        • et al.
        Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
        Eur Heart J. 2016; 37: 455-462